SCN3A-Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation

Tariq Zaman, Katherine L. Helbig, Jérôme Clatot, Christopher H. Thompson, Seok Kyu Kang, Katrien Stouffs, Anna E. Jansen, Lieve Verstraete, Adeline Jacquinet, Elena Parrini, Renzo Guerrini, Yuh Fujiwara, Satoko Miyatake, Bruria Ben-Zeev, Haim Bassan, Orit Reish, Daphna Marom, Natalie Hauser, Thuy Anh Vu, Sally AckermannCareni E. Spencer, Natalie Lippa, Shraddha Srinivasan, Agnieszka Charzewska, Dorota Hoffman-Zacharska, David Fitzpatrick, Victoria Harrison, Pradeep Vasudevan, Shelagh Joss, Daniela T. Pilz, Katherine A. Fawcett, Ingo Helbig, Naomichi Matsumoto, Jennifer A. Kearney, Andrew E. Fry, Ethan M. Goldberg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Objective: Pathogenic variants in SCN3A, encoding the voltage-gated sodium channel subunit Nav1.3, cause severe childhood onset epilepsy and malformation of cortical development. Here, we define the spectrum of clinical, genetic, and neuroimaging features of SCN3A-related neurodevelopmental disorder. Methods: Patients were ascertained via an international collaborative network. We compared sodium channels containing wild-type versus variant Nav1.3 subunits coexpressed with β1 and β2 subunits using whole-cell voltage clamp electrophysiological recordings in a heterologous mammalian system (HEK-293T cells). Results: Of 22 patients with pathogenic SCN3A variants, most had treatment-resistant epilepsy beginning in the first year of life (16/21, 76%; median onset, 2 weeks), with severe or profound developmental delay (15/20, 75%). Many, but not all (15/19, 79%), exhibited malformations of cortical development. Pathogenic variants clustered in transmembrane segments 4 to 6 of domains II to IV. Most pathogenic missense variants tested (10/11, 91%) displayed gain of channel function, with increased persistent current and/or a leftward shift in the voltage dependence of activation, and all variants associated with malformation of cortical development exhibited gain of channel function. One variant (p.Ile1468Arg) exhibited mixed effects, with gain and partial loss of function. Two variants demonstrated loss of channel function. Interpretation: Our study defines SCN3A-related neurodevelopmental disorder along a spectrum of severity, but typically including epilepsy and severe or profound developmental delay/intellectual disability. Malformations of cortical development are a characteristic feature of this unusual channelopathy syndrome, present in >75% of affected individuals. Gain of function at the channel level in developing neurons is likely an important mechanism of disease pathogenesis. ANN NEUROL 2020;88:348–362.

Original languageEnglish
Pages (from-to)348-362
Number of pages15
JournalAnnals of Neurology
Volume88
Issue number2
DOIs
StatePublished - 1 Aug 2020

Funding

FundersFunder number
Wales Gene Park
Minnesota Department of Health
Wales Epilepsy Research Network
March of Dimes Basil O'Connor Research Award
Wellcome Trust
Burroughs Wellcome Fund
Japan Society for the Promotion of Science20K07907, JP17K10080, 16118
Japan Society for the Promotion of Science
Health Innovation Challenge FundHICF‐1009‐003
National Institute of Neurological Disorders and StrokeK08NS097633
National Institute of Neurological Disorders and Stroke
Japan Agency for Medical Research and DevelopmentJP19ek0109348, JP18kk020501, JP19ek0109280, JP19dm0107090, JP19ek0109301
Japan Agency for Medical Research and Development
Newlife the Charity for Disabled Children11‐12/04
Newlife the Charity for Disabled Children
Wellcome Trust Sanger InstituteWT098051

    Fingerprint

    Dive into the research topics of 'SCN3A-Related Neurodevelopmental Disorder: A Spectrum of Epilepsy and Brain Malformation'. Together they form a unique fingerprint.

    Cite this